Query related to Pomalidomide Celgene / Celgene.com

Pomalidomide Celgene : websites on the same subject

1

Pomalyst REMS Home

November 09, 2018

Welcome to the POMALYST REMS ® program. POMALYST ® (pomalidomide), in combination with dexamethasone, is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Link between the website and the query : 97 %

Quality and density of the query / crawled pages : 7,59 %

See details :

pomalystrems.com

2

POMALYST (pomalidomide) - For …

November 09, 2018

Find info on POMALYST + dex for relapsed/refractory myeloma after lenalidomide & proteasome inhibitor. See safety and box warnings on fetal toxicity & blood clots.

Link between the website and the query : 95 %

Quality and density of the query / crawled pages : 3,21 %

See details :

pomalyst.com

3

Pomalidomide in Combination With Low-dose …

November 09, 2018

A phase 2, multicenter, multi-cohort, open-label study of pomalidomide in combination with low-dose dexamethasone or pomalidomide in combination with low-dose dexamethasone and daratumumab in subjects with relapsed or refractory multiple myeloma following lenalidomide based therapy in the first or second line setting.

Link between the website and the query : 91 %

Quality and density of the query / crawled pages : 6,69 %

See details :

clinicaltrials.gov

4

Innovative Therapies Advancing Treatment of ... - …

November 09, 2018

Learn more about Celgene's portfolio of services and innovative therapies that are advancing the treatment of diseases. Find links to product websites and patent information, and download patient or prescribing information.

Link between the website and the query : 89 %

Quality and density of the query / crawled pages : 3,66 %

See details :

celgene.com

5

Celgene REMS Pharmacy Portal

November 09, 2018

To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the Celgene products THALOMID ® (thalidomide), REVLIMID ® (lenalidomide) and POMALYST ® (pomalidomide).

Link between the website and the query : 87 %

Quality and density of the query / crawled pages : 7,82 %

6

Multiple myeloma - Australian Government …

November 09, 2018

Patient eligibility. Treatment with bortezomib can be subsidised through the PBS under the National Health Act 1953, section 100 arrangements - Efficient Funding of Chemotherapy (EFC), for a patient with multiple myeloma.

Link between the website and the query : 87 %

Quality and density of the query / crawled pages : 6,63 %

See details :

humanservices.gov.au

7

Pomalidomide for Lenalidomide for Relapsed or …

November 09, 2018

This is a phase 2, multicenter, open-label and non-randomized study to evaluate the efficacy and safety of pomalidomide as a replacement for lenalidomide among MM patients who have failed lenalidomide-containing regimens that include more than steroids within 6 months of their last dose of lenalidomide.

Link between the website and the query : 86 %

Quality and density of the query / crawled pages : 2,68 %

See details :

clinicaltrials.gov

8

Imnovid 2mg - Summary of Product Characteristics …

November 09, 2018

Imnovid 2mg - Summary of Product Characteristics (SmPC) by Celgene Ltd

Link between the website and the query : 84 %

Quality and density of the query / crawled pages : 6,55 %

See details :

medicines.org.uk

9

Celgene Risk Management

November 09, 2018

To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the Celgene products THALOMID ® (thalidomide), REVLIMID ® (lenalidomide) and POMALYST ® (pomalidomide).

Link between the website and the query : 84 %

Quality and density of the query / crawled pages : 6,10 %

See details :

elgeneriskmanagement.com

10

Patient Enrollment Form | Celgene Patient Support ...

November 09, 2018

Patient Information If applying for co-pay assistance or Celgene Patient Assistance Program (PAP), the patient’s gross family income and number of people living in their household will need to be provided.

Link between the website and the query : 82 %

Quality and density of the query / crawled pages : 3,42 %

11

MULTIPLE MYELOMA (MM) - Celgene

November 09, 2018

Area of Research Phase 1 Phase 2 Phase 3 Post-Approval Research C C F P- esear C- C- T T appr MULTIPLE MYELOMA (MM)

Link between the website and the query : 80 %

Quality and density of the query / crawled pages : 1,27 %

See details :

celgene.com

12

How to Enroll in Celgene Patient Support

November 09, 2018

The Celgene Patient Support ® program is a service provided by Celgene Corporation. Celgene Patient Support ® is not insurance. Celgene does not collect personal information for marketing purposes without your consent.

Link between the website and the query : 78 %

Quality and density of the query / crawled pages : 1,60 %

13

Daratumumab monotherapy in patients with …

November 09, 2018

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Link between the website and the query : 77 %

Quality and density of the query / crawled pages : 2,46 %

See details :

sciencedirect.com

14

Marizomib - Triphase Accelerator Corporation

November 09, 2018

Marizomib is a novel, brain-penetrant proteasome inhibitor, which inhibits all three proteasome subunits. Celgene acquired the assets related to marizomib from Triphase in November 2016 and Triphase continues to support Celgene with development – including completing a Phase 2 study in recurrent glioma and a Phase 1 study in newly diagnosed ...

Link between the website and the query : 72 %

Quality and density of the query / crawled pages : 2,83 %

See details :

riphaseco.com

15

Practice Essentials - Managing Myeloma

November 09, 2018

Managing Myeloma is an educational initiative dedicated to developing tools, information, and resources that support improved therapeutic outcomes for patients diagnosed with multiple myeloma.

Link between the website and the query : 67 %

Quality and density of the query / crawled pages : 8,62 %

See details :

managingmyeloma.com

16

Treatment with DARZALEX® (daratumumab) | HCP

November 09, 2018

CONTRAINDICATIONS. DARZALEX ® is contraindicated in patients with a history of severe hypersensitivity (eg, anaphylactic reactions) to daratumumab or any …

Link between the website and the query : 66 %

Quality and density of the query / crawled pages : 2,48 %

See details :

darzalexhcp.com

17

DARZALEX® (daratumumab) Dosing

November 09, 2018

How Often Is DARZALEX ® Given? Dosing frequency of DARZALEX ® in combination with Revlimid ® (lenalidomide) + dexamethasone or Pomalyst ® (pomalidomide) + dexamethasone and as …

Link between the website and the query : 65 %

Quality and density of the query / crawled pages : 5,75 %

See details :

darzalex.com

18

IMF Patient & Family Seminar: Los Angeles, CA | …

November 09, 2018

We would like to thank: Amgen, Astellas Pharma, Binding Site, Bristol-Myers Squibb, Celgene, Diplomat Pharmacy, Genentech, Hoffmann-La Roche, Janssen, Karyopharm ...

Link between the website and the query : 65 %

Quality and density of the query / crawled pages : 3,40 %

See details :

myeloma.org

19

Apremilast - Wikipedia

November 09, 2018

Apremilast, brand name Otezla among others, is a medication for the treatment of certain types of psoriasis and psoriatic arthritis. It may also be useful for other …

Link between the website and the query : 63 %

Quality and density of the query / crawled pages : 8,11 %

See details :

wikipedia.org

20

Lenalidomide - Wikipedia

November 09, 2018

Lenalidomide (trade name Revlimid) is a derivative of thalidomide approved in the United States in 2005. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment.

Link between the website and the query : 63 %

Quality and density of the query / crawled pages : 0,65 %

See details :

wikipedia.org